Study of XTMAB-16 for Pulmonary Sarcoidosis
Part of Blood & lymphatic, Immune system & allergy, Lungs & breathing clinical trials.
This trial tests an experimental drug called XTMAB-16 for people with sarcoidosis in the lungs, which may also affect other parts of the body. The goal is to see if it helps improve breathing and reduce symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- Your weight must be between 99 and 353 pounds (45 to 160 kg).
- You must have a sarcoidosis diagnosis in your lungs for at least 6 months.
- You must have shortness of breath (score of 1 or more on a standard scale).
- Your lung function test must show at least 50% of expected value.
- You must be taking a daily corticosteroid (like prednisone) at a dose between 5 and 25 mg, and be willing to follow a dose-tapering schedule.
- You cannot have significant lung scarring (fibrosis) over 20%.
- You must not have other serious health conditions or recent treatments that could interfere.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug to see if it can help people with pulmonary sarcoidosis, which affects the lungs. The drug may work by reducing inflammation, and this study will check its safety and effectiveness.
This study tests a new medication, OATD-01, for people with active sarcoidosis in their lungs. It aims to see how safe and effective the drug is and if it can improve symptoms.
This trial tests a steroid medication called compound betamethasone for people with newly diagnosed pulmonary sarcoidosis (stage I or II). It may help reduce inflammation and improve symptoms compared to standard prednisone treatment.
This trial studies a treatment approach for people with active cardiac sarcoidosis, confirmed by specific heart rhythm/heart function problems and a PET scan. It may help by targeting the active inflammation driving heart conduction problems, rhythm events, or weak heart pumping.
This trial tests whether nintedanib, a drug that slows lung scarring, can help people with sarcoidosis-related lung fibrosis. It is for those who still have breathlessness or cough despite stable treatment.
This study follows adults with sarcoidosis to see which body “risk signals” (biomarkers) can predict whether the disease will get better or worse. It may help doctors monitor sarcoidosis more closely and choose the right treatment sooner.
Hear when a new Pulmonary Sarcoidosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.